The results from other ongoing clinical trials are eagerly awaited, in particular the evaluation of the theranostic couple [68Ga]Ga/[177Lu]Lu-NeoBOMB1 in patients with GRPR-expressing malignancies, including ER-positive/HER2-negative breast cancer led by Novartis (86). Here, ERBB2 is linked to breast cancer.